WSJ BLOG/Health: A.M. Vitals: Study Shows Cancer Risk for Children Getting CT Scans

Date : 06/07/2012 @ 9:26AM
Source : Dow Jones News
Stock : Novartis Ag (NVS)
Quote : 84.85  0.65 (0.77%) @ 4:02PM

WSJ BLOG/Health: A.M. Vitals: Study Shows Cancer Risk for Children Getting CT Scans

Novartis (NYSE:NVS)
Historical Stock Chart

5 Years : From Jul 2012 to Jul 2017

Click Here for more Novartis Charts.

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Mark Long

Here's what's making health news this morning:

Children's CT Scans Pose Cancer Risk (WSJ): Getting two to three computed tomography head exams makes children and adolescents three times as likely to develop brain cancer--though the absolute risk is small--a study of 176,587 people published in The Lancet showed.

DNA Blueprint for Fetuses Built Using Tests of Parents (New York Times): Scientists reported in a paper in Science Translational Medicine that they used new, high-speed sequencing and computational tools to deduce the DNA sequence of the fetus using a blood sample from the pregnant woman and saliva from the father.

New Cancer-Gene Test Seeks to Match Drugs to Patients (WSJ): Foundation Medicine disclosed that Novartis will use its new test to genetically analyze tumors in most patients in early stage clinical trials of the Swiss drug maker's experimental treatments.

Novartis Unit Recalling Birth Control Pills (WSJ): The FDA said the unit, Sandoz, is recalling 10 lots of the Introvale pills sold in the U.S. because of a packing error.

Vaccines for U.S. Children May Not Be Properly Stored--Study (Reuters): A report from the Office of the Inspector General in the Department of Health and Human Services found free vaccines meant for kids in a federal program may have been stored at the wrong temperature.

FDA Approves Glaxo, XenoPort Drug Horizant for Shingles-Related Disease (Dow Jones Newswires): Approval of the drug to manage postherpetic neuralgia, which affects about 100,000 Americans, follows three clinical studies involving 574 adults.

First Tuberculosis Drug in 40 Years Has Otsuka Cautious (Bloomberg News): A study published in the New England Journal of Medicine shows the Japanese company's delamanid helped fight TB strains not halted by other treatments. Otsuka plans to restrict access to avoid resistance to the drug building up.

 
 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 
 

Latest NVS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.